可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1]Ni YG, Wang N, Oh M,et al . Foxo transcription factors blunt cardiac hypertrophy by inhibiting calcineurin signaling[J]. Circulation, 2006,114(11):1159-1168.
[2]Yu LJ, Zhu SJ, Zhou YZ,et al . Angiotensin II induced cardiac hypertrophy is blocked by PTEN via suppressing Ca2+/Calcineurin pathway[J]. Zhonghua Xin Xue Guan Bing Za Zhi, 2006,34(6):541-545.
[3]Molkentin JD, Lu JR, Antos CL,et al . A calcineurindependent transcriptional pathway for cardiac hypertrophy[J]. Cell, 1998, 93(2): 215-228.
[4]Rusnak F,Mertz P. Calcineurin: form and function[J]. Physiol Rev, 2000, 80(4): 1483-1521.
[5]Bustin SA. Absolute quantification of mRNA using realtime reverse transcription polymerase chain reaction assays[J]. J Mol Endocrinol, 2000, 25(2): 169-193.
[6]Rasmussen R. Quantification on the light cycler[M]//Meuer S,Wittwer C,Nakagawara K. Rapid cycle realtime PCR, methods and applications. Heidelberg: Springer Press, 2001,21-34.
[7]Klein D. Quantification using realtime PCR technology: applications and limitations. [J]. Trends Mol Med, 2002, 8(6):257-260.
[8]Tsao L, Neville C, Musaro A,et al . Revisiting calcineurin and human heart failure[J]. Net Med, 2000, 6(1): 2-3.
[9]Kamiya H, Okumura K, Ito M,et al . Calcineurin inhibitor attenuates cardiac hypertrophy due to energy metabolic disorder[J]. Can J Cardiol, 2001, 17(12):1292-1298.
[10]Zou Y, Hiroi Y, Uozumi H,et al . Calcineurin plays a critical role in thedevelopment of pressure overload induced cardiac hypertrophy[J]. Circulation, 2001, 104(1): 97-101.
[11]Takeda Y, Yoneda T, Demura M,et al . Calcineurin inhibition attenuates mineralocorticoidinduced cardiac hypertrophy[J]. Circulation, 2002,105(6): 677-679.
[12]张海燕,廖玉华,魏宇淼,等.血管紧张素Ⅱ介导的大鼠血管平滑肌细胞STAT1激活与核转位[J].心脏杂志,2007,19(1):16-19.